This page compares what is documented about CagriSema and Tirzepatide, rather than ranking them by effect. What each molecule is, the sizes and prices actually carried, what the certificate covers, and how the two differ on the bench. Everything here is research-use-only material and we do not publish outcome, dosing or administration content for any compound in the catalogue.
What is CagriSema and what is Tirzepatide?
CagriSema. CagriSema refers to cagrilintide and semaglutide studied in combination rather than to a single new molecule, which makes specification a question about two materials, not one.
Tirzepatide. Tirzepatide is the reference dual GIP/GLP-1 receptor agonist in the literature, and it anchors much of the comparative work newer incretin analogues are measured against.
How do CagriSema and Tirzepatide compare on price and size?
| CagriSema | Tirzepatide | |
|---|---|---|
| Sizes carried | 5 mg, 10 mg, 20 mg | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg |
| From | $75.00 | $50.00 |
| Best price per unit | $7.50 / mg | $2.17 / mg |
| Availability | Backordered — waitlist | Backordered — waitlist |
| Certificate | Lot certificate on the product page | Lot certificate on the product page |
| Molecular formula | — | C225H348N48O68 |
| Molar mass | — | 4,813 g/mol |
| Source | — | PubChem CID 166567236 |
| Research area | combination metabolic pharmacology | GIP/GLP-1 receptor research |
At their best sizes Tirzepatide works out at $2.17 per mg against $7.50 for CagriSema — 3.5 times more for the mg. Vial prices start at $75.00 and $50.00 respectively, which is the number most people compare and the one that says least, because the two are not sold in the same sizes. Full sizes, tier pricing and the lot certificate sit on the CagriSema page and the Tirzepatide page.
What is each one studied for?
What the published literature investigates, which is a different question from what either will do, and the only one of the two a supplier can answer.
CagriSema is studied in combination metabolic pharmacology research. Combination approaches are where much of the current incretin literature is concentrated.
Tirzepatide is studied in gip/glp-1 receptor research. Dual-agonist incretin research keeps expanding, and tirzepatide remains the benchmark compound most new metabolic work is compared against.
Studied in the same area does not make two compounds interchangeable, and the research library holds the per-compound documentation.
Tirzepatide vs CagriSema: how they differ on the bench
Tirzepatide. Our tirzepatide storage guide is one of the most-read pages on the site: sealed powder archives cold and dark, and prepared solutions get dated the day they are made.
CagriSema. A combination listing should tell you what is in the vial and in what proportion. If it does not, the certificate is the place that answer has to come from.
What actually differs between Tirzepatide and CagriSema
Molar mass is not published for both of these, so the mass-to-amount conversion below is left undone rather than estimated. Where a formula and a molecular weight exist they are in the table above, carried with the PubChem record they came from; where they are not, the lot certificate is the document that settles what the material is.
Identity is the other analytical axis, and it is settled per lot rather than per compound. Tirzepatide. Catalogued as Tirzepatide, and the certificate's identity test resolves to that.
Both are released against a certificate reporting identity, purity by the stated method and net peptide content, readable before anything is bought.
Which is better, Tirzepatide or CagriSema?
Neither Tirzepatide nor CagriSema is ranked against the other here, and the refusal is deliberate. Better, safer and stronger are questions about effects in a living system, and we sell neither compound for use in one — why none of these pages ranks two compounds sets out the reasoning in full.
What it does instead, for these two:
- Tirzepatide is the cheaper of the two per mg, at $2.17 against $7.50.
- CagriSema is carried in 3 sizes and Tirzepatide in 14, and each lot carries its own certificate.
Every one of those is checkable before you buy.
Common questions
What is the difference between Tirzepatide and CagriSema?
Tirzepatide is the reference dual GIP/GLP-1 receptor agonist in the literature, and it anchors much of the comparative work newer incretin analogues are measured against. CagriSema refers to cagrilintide and semaglutide studied in combination rather than to a single new molecule, which makes specification a question about two materials, not one.
Which one should I choose?
CagriSema is carried in 5 mg, 10 mg, 20 mg and Tirzepatide in 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, each lot with its own certificate. Which of those suits the work is yours to decide; everything here is research-use-only rather than guidance for use in a human or an animal.
Do both CagriSema and Tirzepatide come with a certificate of analysis?
Neither is in stock at the moment, so in each case the certificate is the one attached to the lot that arrives. A certificate belongs to a lot, not to a product. It is linked from the product page, and reports identity, purity by the stated method, and net peptide content for the material actually in that lot.
Which is cheaper, Tirzepatide or CagriSema?
Per mg, Tirzepatide at $2.17 against $7.50, taking each one's best size. By vial they start at $75.00 for CagriSema and $50.00 for Tirzepatide, which is the comparison most people make and the one that says least, because the two are not sold in the same sizes.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.